Revolution Medicines is dedicated to discovering, developing, and delivering innovative targeted medicines for cancer patients. The company focuses on RAS-addicted cancers, which represent 30 percent of new human cancer diagnoses. Revolutionaries work tirelessly to develop cutting-edge therapeutic approaches, setting them apart in the industry with their commitment to tackling some of the toughest cancers.
Revolution Medicines is a precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The Director of Biostatistics will lead clinical program strategy, support clinical development, and serve as a subject matter expert in Biostatistics for quantitative sciences, responsible for product life cycle support and data-driven insights. The role involves statistical support for study protocol, data analysis, and compliance with regulatory guidelines.
Revolution Medicines is dedicated to discovering, developing, and delivering innovative targeted medicines for cancer patients. The company focuses on RAS-addicted cancers, which represent 30 percent of new human cancer diagnoses. Revolutionaries work tirelessly to develop cutting-edge therapeutic approaches, setting them apart in the industry with their commitment to tackling some of the toughest cancers.